Proteomic approach to identify biomarkers for invasive cervix cancer - a prospective pilot study

Purpose of Investigation: Cervical cancer (CC) is the second most common cancer of women worldwide and a leading cause of mortality. Unfortunately, this disease has no current viable serum biomarkers capable of diagnosing CC or predicting prognosis. The present authors’ objective was to examine novel serum biomarkers capable of identifying patients with invasive CC and determine their utility in monitoring disease status. Materials and Methods: In this IRB approved prospective study, luminex bead array was used to measure 18 different serum protein concentrations in CC patients (n=23), women with precancerous lesions (CIN2-3) (n=20) and patients with normal cervical cytology (n=20). CC patients had blood samples drawn within 30 days of diagnosis and repeat samples post-completion of therapy. MMP7 expression was confirmed by immunohistochemistry (IHC) and scored independently by two pathologists. Results: Multiple proteins had different levels in CC, controls, and CIN (p < 0.05). MMP7 was most promising for identifying invasive cancer (sensitivity of 88.9%, specificity 95%, p < 0.001). IHC confirmed MMP7 expression in invasive CC. MMP7 serum levels were an indicator for progression-free survival (PFS) (HR 3.82, CI: 1.10–13.29, p = 0.025) and overall survival (OS) (HR 7.96, CI: 0.91– 69.32, p = 0.03). Conclusion: MMP7 serum concentration was altered when comparing CC, controls, and CIN2-3, and shows potential as being a future biomarker for both identifying invasive CC and patient prognosis. Based on this study, MMP7 warrants further investigation as a biomarker of invasive CC.

Cervical cancer; Serum proteomics; Biomarkers.

[1] Ibeanu O.A.: “Molecular pathogenesis of cervical cancer”. Cancer Biol. Ther., 2011, 11, 295.

[2] Franco L.E., Schlecht F.N., Saslow D.: “The epidemiology of cervical cancer”. Cancer J., 2003, 9, 348.

[3] Tewari K.S., Sill M.W., Long H.J. 3rd., Penson R.T., Huang H., Ramondetta L.M., et al.: “Improved survival with bevacizumab in advanced cervical cancer”. New Engl. J. Med., 2014, 370, 734.

[4] Partridge E.E., Abu-Rustum N.R., Campos S.M., Fahey P.J., Farmer M., Garcia R.L., et al.: “Cervical cancer screening”. J. Natl. Compr. Canc. Netw., 2010, 8, 1358.

[5] Goldie S.J., Kuhn L., Denny L., Pollack A., Wright T.C.: “Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness”. JAMA, 2001, 285, 3107.

[6] Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S.: “Human papillomavirus and cervical cancer”. Lancet, 2007, 370, 890.

[7] Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D. Jr., Penny M.E., Aranda C., et al.: “Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males”. New Engl. J. Med., 2011, 364, 401.

[8] Waggoner S.E.: “Cervical cancer”. Lancet, 2003, 361, 2217.

[9] Gadducci A., Cosio S., Carpi A., Nicolini A., Genazzani A.R.: “Serum tumor markers in the management of ovarian, endometrial and cervical cancer”. Biomed. Pharmacother., 2004, 58, 24.

[10] Gadducci A., Tana R., Cosio S., Genazzani A.R.: “The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature”. Crit. Rev. Oncol. Hematol., 2008, 66, 10.

[11] Smith L., Lind M.J., Welham K.J., Cawkwell L., Cancer Biology Proteomics Group: “Cancer proteomics and its application to discovery of therapy response markers in human cancer. Cancer, 2006, 107, 232.

[12] Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al.: “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)”. Eur. J. Cancer, 2009, 45, 228.

[13] Huang Y.F., Shen M.R., Hsu K.F., Cheng Y.M., Chou C.Y.: “Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer”. Br. J. Cancer, 2008, 99, 1096.

[14] Mathur S.P., Mathur R.S., Gray E.A., Lane D., Underwood P.G., Kohler M., et al.: “Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]”. Gynecol. Oncol., 2005, 98, 467.

[15] Sheu B.C., Lien H.C., Ho H.N., Lin H.H., Chow S.N., Huang S.C., et al.: “Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer”. Cancer Res., 2003, 63, 6537.

[16] Herfs M., Yamamoto Y., Laury A., Wang X., Nucci M.R., McLaughlin-Drubin M.E., et al.: “A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer”. Proc. Natl. Acad. Sci. U S A, 2012, 109, 10516.

[17] Wu S.H., Zhang J., Li Y., Li J.M.: “Expression of ETV5 and MMP7 in early stage cervical squamous cell carcinoma and its role in lymphatic metastasis”. Ai Zheng, 2006, 25, 315.

[18] Klupp F., Neumann L., Kahlert C., Diers J., Halama N., Franz C., et al.: “Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients”. BMC Cancer, 2016, 16, 494.

[19] Wang S.C., Parekh J.R., Porembka M.R., Nathan H., D’Angelica M.I., DeMatteo R.P., et al.: “A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients”. J. Gastrointest. Surg., 2016, 20, 899.

[20] Renema N., Navet B., Heymann M.F., Lezot F., Heymann D.: “RANK-RANKL signalling in cancer”. Biosci. Rep., 2016, 36, pii: e00366.

[21] Demoulin S.A., Somja J., Duray A., Guenin S., Roncarati P., Delvenne P.O., et al.: “Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion”. Oncoimmunology, 2015, 4, e1008334.

[22] Shang W.Q., Li H., Liu L.B., Chang K.K., Yu J.J., Xie F., et al.: “RANKL/RANK interaction promotes the growth of cervical cancer cells by strengthening the dialogue between cervical cancer cells and regulation of IL-8 secretion”. Oncol. Rep., 2015, 34, 3007.

[23] Yoldi G., Pellegrini P., Trinidad E.M., Cordero A., Gomez-Miragaya J., Serra-Musach J., et al.: “RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation”. Cancer Res., 2016, 76, 5857.

[24] Weber G.F., Lett G.S., Haubein N.C.: “Osteopontin is a marker for cancer aggressiveness and patient survival”. Br. J. Cancer, 2010, 103, 861.

[25] Maeda N., Ohashi T., Chagan-Yasutan H., Hattori T., Takahashi Y., Harigae H., et al.: “Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia”. Retrovirology, 2015, 12, 99.

[26] Huang X., Qian Y., Wu H., Xie X., Zhou Q., Wang Y., et al.: “Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinoma”. J. Histochem. Cytochem., 2015, 63, 88.